Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: “JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum”

International Journal of DermatologyEarly View Correspondence Refractory pyoderma gangrenosum associated with rheumatoid arthritis successfully treated with upadacitinib. Comments on: "JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum" Mayra Rabelo dos Santos MD, Corresponding Author Mayra Rabelo dos Santos MD [email protected] Hospital de Doenças Tropicais Dr Anuar Auad, Goiânia, Goiás, BrazilSearch for more papers by this authorMayra Ianhez MD, PhD, Mayra Ianhez MD, PhD orcid.org/0000-0003-3604-3128 Hospital de Doenças Tropicais Dr Anuar Auad, Goiânia, Goiás, BrazilSearch for more papers by this authorBruno Nazeozeno Ribeiro MD, Bruno Nazeozeno Ribeiro MD Centro Médico Alameda, Goiânia, Goiás, BrazilSearch for more papers by this authorBoaventura Braz de Queiroz MD, Boaventura Braz de Queiroz MD Hospital de Doenças Tropicais Dr Anuar Auad, Goiânia, Goiás, BrazilSearch for more papers by this authorHelio Amante Miot PhD, Helio Amante Miot PhD orcid.org/0000-0002-2596-9294 Universidade Estadual Paulista Júlio de Mesquita Filho - Campus de Botucatu, Botucatu, São Paulo, BrazilSearch for more papers by this author Mayra Rabelo dos Santos MD, Corresponding Author Mayra Rabelo dos Santos MD [email protected] Hospital de Doenças Tropicais Dr Anuar Auad, Goiânia, Goiás, BrazilSearch for more papers by this authorMayra Ianhez MD, PhD, Mayra Ianhez MD, PhD orcid.org/0000-0003-3604-3128 Hospital de Doenças Tropicais Dr Anuar Auad, Goiânia, Goiás, BrazilSearch for more papers by this authorBruno Nazeozeno Ribeiro MD, Bruno Nazeozeno Ribeiro MD Centro Médico Alameda, Goiânia, Goiás, BrazilSearch for more papers by this authorBoaventura Braz de Queiroz MD, Boaventura Braz de Queiroz MD Hospital de Doenças Tropicais Dr Anuar Auad, Goiânia, Goiás, BrazilSearch for more papers by this authorHelio Amante Miot PhD, Helio Amante Miot PhD orcid.org/0000-0002-2596-9294 Universidade Estadual Paulista Júlio de Mesquita Filho - Campus de Botucatu, Botucatu, São Paulo, BrazilSearch for more papers by this author First published: 10 July 2023 https://doi.org/10.1111/ijd.16791 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Castro LGM. JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum. Int J Dermatol. 2023; 62: 1088–93. https://doi.org/10.1111/ijd.16676 2Kridin K, Cohen AD, Amber KT. Underlying systemic diseases in pyoderma gangrenosum: a systematic review and meta-analysis. Am J Clin Dermatol. 2018; 19: 479–87. https://doi.org/10.1007/s40257-018-0356-7 3Syed K, Chaudhary H, Balu B. Pyoderma gangrenosum following COVID-19 infection. J Community Hosp Intern Med Perspect. 2021; 11: 601–3. https://doi.org/10.1080/20009666.2021.1958492 4Orfaly VE, Kovalenko I, Tolkachjov SN, Ortega-Loayza AG, Nunley JR. Tofacitinib for the treatment of refractory pyoderma gangrenosum. Clin Exp Dermatol. 2021; 46: 1082–5. https://doi.org/10.1111/ced.14683 5Nasifoglu S, Heinrich B, Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol. 2018; 179(2): 504–5. https://doi.org/10.1111/bjd.16468 6Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. JAK-STAT pathway inhibitors in dermatology. An Bras Dermatol. 2023:S0365-0596(23)00114-9. https://doi.org/10.1016/j.abd.2023.03.001. 7Maronese CA, Pimentel MA, Li MM, Genovese G, Ortega-Loayza AG, Marzan AV. Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments. Am J Clin Dermatol. 2022; 23(5): 615–34. https://doi.org/10.1007/s40257-022-00699-8 8Kozono K, Nakahara T, Kikuchi S, Itoh E, Kido-Nakahara M, Furue M. Pyoderma gangrenosum with increased levels of serum cytokines. J Dermatol. 2015; 42(12): 1186–8. https://doi.org/10.1111/1346-8138.12970 9Lee WS, Choi YJ, Yoo WH. Use of tocilizumab in a patient with pyoderma gangrenosum and rheumatoid arthritis. J Eur Acad Dermatol Venereol. 2017; 31(2): e75–7. https://doi.org/10.1111/jdv.13736 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation